Managed access program for atrasentan
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This program provides access to atrasentan for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious or life-threatening disease.
- No comparable or satisfactory alternative treatment is available.
- You are not eligible for or cannot join a clinical trial.
- The potential benefit of the treatment is greater than the risks.
- Your doctor has requested the treatment, and local laws allow it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
This study collects real-world information from people with IgA nephropathy who are being treated with one of two medicines, iptacopan or atrasentan. The goal is to understand how these treatments work in everyday practice, which may help improve care for others with the condition.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
This program provides access to an experimental medicine called ianalumab for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. Your doctor must request this medicine for you, and the company (Novartis) will review each request individually.
This program provides early access to a Novartis study drug for patients with serious or life-threatening conditions who have no other treatment options. It aims to help patients who cannot join a clinical trial.
This program provides access to an investigational medication called eltrombopag for people with serious or life-threatening conditions who have no other good treatment options. It is only available through a doctor's formal request and is not part of a clinical trial.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.